

Media Contacts

Kirsty Langton 01635 206513

FOR IMMEDIATE RELEASE

BAXTER TO FUND TWO RESEARCH STUDIES TO EXPAND CLINICAL EVIDENCE OF HOME DIALYSIS THERAPIES

COMPTON, 8th December 2011: Two UK nephrologists are to carry out studies into the support of home dialysis treatments following grants totaling over £200,000 from Baxter.

Professor Edwina Brown from Imperial College Healthcare NHS Trust has been awarded a grant to fund a 3 year study of Assisted Automated Peritoneal Dialysis (aAPD) patients compared to those on hospital haemodialysis within a frail, older patient population. Professor Brown said, "We want to find out if frail patients on aAPD have improved outcomes compared to patients on hospital dialysis. We will also be comparing the non-dialysis therapy costs of aAPD and haemodialysis for older patients including transport, outpatient and inpatient hospital visits."

The other grant has been awarded to Dr Sandip Mitra from the Central Manchester Foundation NHS Trust & the University of Manchester who will be investigating patient pathways and adoption barriers to home haemodialysis. Dr Mitra said, "Despite national guidance, physician preferences and increasing evidence of superior benefits of extended dialysis regimes at home, the uptake and prevalence of this modality remains low in UK. This project will be a two year multicentre study to understand and analyse the drivers to introducing and sustaining this modality of care which is fundamental to realizing the full benefits of home haemodialysis for patients and the NHS."

Baxter Medical Director Joubert Gama said, "We are delighted that we have been able to support further research into home therapies such as PD and home haemodialysis. Home based treatments offer many benefits to patients as they negate the need to travel to and from hospital for regular thrice weekly treatment. Home therapies also develop patient autonomy."

ENDS

Note to Editors:

The Baxter Clinical Evidence Council facilitates and evaluates research focused on expanding the clinical evidence supporting peritoneal dialysis therapy and home hemodialysis therapy.

About Baxter

Baxter Healthcare Ltd. is the primary domestic operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter is a global, diversified healthcare company that develops products and therapies to make a meaningful difference in the lives of people with life-threatening conditions such as haemophilia, kidney disease, immune disorders and other chronic and acute conditions.